ArticleSurgery today2026
Impact of the Cachexia Index on survival and recurrence in patients undergoing surgery for gastric cancer.
Article in Surgery today, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeThis study aimed to elucidate the clinical relevance of the cachexia index (CXI), an integrative metric encompassing sarcopenia, nutritional status, and systemic inflammatory burden, in patients undergoing surgery for gastric cancer (GC).
methodsWe retrospectively reviewed 1,166 patients who underwent curative gastrectomy for GC. The CXI was calculated as follows: skeletal muscle index (SMI) × serum albumin concentration (g/dL) / neutrophil-to-lymphocyte ratio (NLR). Patients were dichotomized according to sex-specific lowest quartile cutoff values (61.6 for men and 49.2 for women). The impact of the CXI on overall survival (OS), disease-free survival (DFS), and the recurrence patterns was studied. Multivariate Cox regression analyses were performed to identify any independent predictive factors for a poor survival.
resultsA low CXI was significantly associated with advanced age (≥ 65 years), a higher comorbidity burden, an advanced pathological stage, and a higher incidence of postoperative complications. Patients in the low-CXI group had a significantly poorer OS than those in the high-CXI group (5-year OS: 63.4% vs. 78.5%, P < 0.001), with a consistently inferior survival across pathological stages I-III. A low CXI was also significantly associated with a poorer DFS (5-year DFS: 61.0% vs. 76.7%, P < 0.001). Among the patients with stage II/III disease, hematogenous recurrence occurred more frequently in the low-CXI group than in the high-CXI group (13.6% vs. 6.9%, P = 0.026). A multivariate analysis revealed that a low CXI was an independent predictor of a poor OS (HR 1.58, 95% CI: 1.20-2.07, P = 0.001).
conclusionsThe CXI is useful for predicting the survival outcomes of GC patients, irrespective of tumor stage. A low CXI was associated with a higher incidence of recurrence, especially hematogenous recurrence.
Indexed as
Identifiers
42439925What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.